Minireview
British Journal of Cancer (2005) 93, 613–619. doi:10.1038/sj.bjc.6602774 www.bjcancer.com
Published online 6 September 2005
Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
J B Bartlett1, A Tozer1, D Stirling1 and J B Zeldis1
1Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA
Correspondence: Dr JB Bartlett, E-mail: bbartlett@celgene.com
Received 18 July 2005; Revised 10 August 2005; Accepted 10 August 2005; Published online 6 September 2005.
Abstract
Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.
Keywords:
lenalidomide, thalidomide, multiple myeloma, myelodysplastic syndromes, immunomodulatory, angiogenesis
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
NEWS AND VIEWS
Hematology Lenalidomide plus dexamethasone is effective in multiple myeloma
Nature Reviews Clinical Oncology News and Views (01 May 2009)
